Hedera's Fundamental Flaws Challenge Its Long-Term DeFi Prospects Amid Intensifying Sell-Off
- HBAR's 2.5% drop below $0.1480 triggered heavy selling, with 168.9M tokens traded as institutional distribution accelerated. - Liquidity concerns emerged after a 14-minute trading halt and 138% volume spike failed to stabilize the $0.1486 resistance level. - Hedera's Wrapped Bitcoin integration aims to boost DeFi adoption but hasn't offset immediate bearish momentum or liquidity fractures. - Technical indicators show breakdown risk with key support at $0.1382, as sellers dominate with a risk-reward profi
HBAR's latest price movements have ignited discussions among market participants regarding whether the token's steep drop offers a buying window or reveals underlying vulnerabilities. On Nov. 16, the cryptocurrency dropped 2.5% to $0.1480,
The downward trend deepened on Nov. 17, as
Although technical challenges persist, some experts maintain that Hedera's long-term outlook remains positive. The integration of
At present, the risk-to-reward ratio appears to favor sellers, with a breach below $0.1440 likely targeting the $0.1382 mark. While optimistic traders may look for a buying opportunity if the price steadies, the ongoing lack of strong buying and liquidity issues suggest that downward movement remains the most probable scenario. Investors should keep an eye on trading volumes and significant resistance points before making new commitments.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP News Today: SEC Approves Altcoin ETFs, Boosting Institutional Investment in Cryptocurrency
- SEC approves multiple XRP/DOGE ETFs from 21Shares, Franklin Templeton, and Grayscale, signaling growing institutional acceptance of altcoins. - 21Shares' TOXR ETF gains automatic approval via CME CF XRP-Dollar tracking, with Coinbase and BNY Mellon handling custody/admin functions. - Franklin Templeton's XRP Trust removes restrictive clauses to accelerate listing, offering regulated exposure without custody risks from ledger forks. - Grayscale expands crypto offerings with XRP/DOGE ETFs on NYSE, joining
Germany's Solar Turning Point: Spotlight on Legislation, Infrastructure, and Ideological Differences
- Germany's SolarPlus Forum 2025 emphasized legislative clarity, funding innovation, and cross-sector collaboration to accelerate solar adoption amid evolving energy policies. - Outdated regulations and permitting hurdles were highlighted as barriers, with calls to align Bundestag reforms with market demands like gas surcharge removal by 2026. - Cement industry growth (5.7% CAGR) and green innovations support infrastructure needs, though energy cost volatility and compliance challenges persist. - Internati
Polkadot Latest Updates: ECB Raises Concerns: Cryptocurrency and Stock Market Downturns Resemble Dot-Com Bubble Threats
- ECB warns U.S. equity/crypto corrections threaten stability, urging central banks to retain rate-cut flexibility amid market volatility. - JPMorgan links crypto ETF outflows to retail investor behavior, noting $4B November sales contrast with $96B equity ETF inflows. - U.S. Treasury downplays recession risks, citing 2026 growth optimism despite shutdown impacts and services-driven inflation. - MSCI highlights tech valuation risks akin to dot-com era, while DeFi faces $12B liquidity crisis with 95% capita
Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats
- Novartis raised 2030 sales growth targets to 5-6% annually, driven by high peak sales expectations for oncology drugs Kisqali and Scemblix. - CEO Vas Narasimhan highlighted eight de-risked drugs with $3-10B peak potential, but analysts warned of patent expirations and uncertain pipeline progress beyond 2030. - Shares rose 0.5% post-announcement, while Exact Sciences surged 17% on its $105/share acquisition by Abbott and Samsung Biologics saw a 71% valuation re-rating after spin-off. - J.P. Morgan caution
